The global enzymatic DNA synthesis market is estimated to be USD 0.296 billion in 2024 and is expected to reach USD 3.90 billion by 2035, with a CAGR of 26.43% during the forecast period 2025-2035. The market will grow due to factors such as the rising need for eco-friendly and sustainable processes, expanding applications in biotechnology and healthcare, growing demand for synthetic DNA, technological advancements in DNA synthesis, and rising use of DNA-based data storage solutions.
The enzymatic DNA synthesis market plays a crucial role in the healthcare sector, particularly in the development of targeted therapies, diagnostics, and vaccines, including mRNA vaccines. Biotechnology companies are increasingly utilizing synthetic DNA for advancements in personalized medicine, particularly in areas such as CAR-T cell therapy and gene editing. The enzymatic DNA synthesis approach facilitates rapid production, enabling prompt responses to emerging health threats. In June 2024, Ansa Biotechnologies, Inc., a recognized partner in complex DNA synthesis, announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Notably, Ansa is the only company capable of synthesizing complete, contiguous DNA oligonucleotides up to 600 base pairs in length without the need for assembly, providing products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments.
By service, the oligonucleotide synthesis segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the high demand for oligonucleotides in various research and diagnostic applications, including PCR, qPCR, and next-generation sequencing (NGS), where they serve as essential primers and probes. For instance, Ansa Biotechnologies, Inc., the reliable partner for complicated DNA synthesis, said today that it is growing its early access program for its services in May 2024. More clients worldwide will benefit from the company's cutting-edge enzymatic DNA synthesis technology, which will spur innovation in life science research, healthcare, and other synthetic DNA-powered industries. Additionally, the gene synthesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of synthetic genes for applications in synthetic biology, genetic engineering, and therapeutic development, particularly in personalized medicine and gene therapy.
By application, the synthetic biology segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the increasing applications of synthetic biology in industrial biotechnology, agricultural genomics, and healthcare. For instance, in August 2024, Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announced key milestones for therapeutic DNA target accuracy and technology automation for the Defense Advanced Research Projects Agency (DARPA) project called NOW (Nucleic Acids On-Demand Worldwide). Under the direction of GE HealthCare's Technology and Innovation Center (previously GE Research), a multidisciplinary team is working on this ambitious initiative that aims to make it possible to produce DNA-based vaccinations and treatments anywhere in the globe in a matter of days. Additionally, the vaccine development segment is predicted to grow at the fastest CAGR during the forecast period owing to its critical role in the rapid design and production of DNA-based vaccines, including mRNA and plasmid DNA vaccines.
By end-user, the Biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the extensive use of synthetic DNA in drug discovery, genetic research, and biologics production. For instance, in April 2024, Ginkgo Bioworks (NYSE: DNA), which is developing the industry-leading platform for cell programming and biosecurity, and Prozomix, a UK-based biotech business specializing in the discovery and production of innovative biocatalysts, announced a new collaboration. Ginkgo and Prozomix are working together to expand the manufacturing of next-generation enzyme plates for the production of active pharmaceutical ingredients (APIs). This partnership intends to take advantage of Prozomix's established enzyme libraries and extensive experience in the production of enzyme plates, as well as Ginkgo's Enzyme Services and industry-leading AI/ML models. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing outsourcing trend in the pharmaceutical and biotechnology industries, where CROs play a key role in providing DNA synthesis services for preclinical and clinical research.
North American region is anticipated to have the highest revenue share during the forecast period owing to the established presence of leading biotechnology and pharmaceutical companies, significant investments in genetic research and synthetic biology, and strong support from government initiatives and funding for genomics and DNA synthesis innovations. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of biotechnology and pharmaceutical industries, increasing government support for life sciences research, and growing investments in synthetic biology and gene therapy. For instance, Evonetix completed a US$24 million financing round in February 2023, bringing its total Series B investment to about US$54 million. Evonetix will be able to continue commercially developing its semiconductor chips thanks to the cash.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
The enzymatic DNA synthesis market plays a crucial role in the healthcare sector, particularly in the development of targeted therapies, diagnostics, and vaccines, including mRNA vaccines. Biotechnology companies are increasingly utilizing synthetic DNA for advancements in personalized medicine, particularly in areas such as CAR-T cell therapy and gene editing. The enzymatic DNA synthesis approach facilitates rapid production, enabling prompt responses to emerging health threats. In June 2024, Ansa Biotechnologies, Inc., a recognized partner in complex DNA synthesis, announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Notably, Ansa is the only company capable of synthesizing complete, contiguous DNA oligonucleotides up to 600 base pairs in length without the need for assembly, providing products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments.
By service, the oligonucleotide synthesis segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the high demand for oligonucleotides in various research and diagnostic applications, including PCR, qPCR, and next-generation sequencing (NGS), where they serve as essential primers and probes. For instance, Ansa Biotechnologies, Inc., the reliable partner for complicated DNA synthesis, said today that it is growing its early access program for its services in May 2024. More clients worldwide will benefit from the company's cutting-edge enzymatic DNA synthesis technology, which will spur innovation in life science research, healthcare, and other synthetic DNA-powered industries. Additionally, the gene synthesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising adoption of synthetic genes for applications in synthetic biology, genetic engineering, and therapeutic development, particularly in personalized medicine and gene therapy.
By application, the synthetic biology segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the increasing applications of synthetic biology in industrial biotechnology, agricultural genomics, and healthcare. For instance, in August 2024, Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announced key milestones for therapeutic DNA target accuracy and technology automation for the Defense Advanced Research Projects Agency (DARPA) project called NOW (Nucleic Acids On-Demand Worldwide). Under the direction of GE HealthCare's Technology and Innovation Center (previously GE Research), a multidisciplinary team is working on this ambitious initiative that aims to make it possible to produce DNA-based vaccinations and treatments anywhere in the globe in a matter of days. Additionally, the vaccine development segment is predicted to grow at the fastest CAGR during the forecast period owing to its critical role in the rapid design and production of DNA-based vaccines, including mRNA and plasmid DNA vaccines.
By end-user, the Biopharmaceutical companies segment accounted for the highest revenue-grossing segment in the global enzymatic DNA synthesis market in 2024 owing to the extensive use of synthetic DNA in drug discovery, genetic research, and biologics production. For instance, in April 2024, Ginkgo Bioworks (NYSE: DNA), which is developing the industry-leading platform for cell programming and biosecurity, and Prozomix, a UK-based biotech business specializing in the discovery and production of innovative biocatalysts, announced a new collaboration. Ginkgo and Prozomix are working together to expand the manufacturing of next-generation enzyme plates for the production of active pharmaceutical ingredients (APIs). This partnership intends to take advantage of Prozomix's established enzyme libraries and extensive experience in the production of enzyme plates, as well as Ginkgo's Enzyme Services and industry-leading AI/ML models. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing outsourcing trend in the pharmaceutical and biotechnology industries, where CROs play a key role in providing DNA synthesis services for preclinical and clinical research.
North American region is anticipated to have the highest revenue share during the forecast period owing to the established presence of leading biotechnology and pharmaceutical companies, significant investments in genetic research and synthetic biology, and strong support from government initiatives and funding for genomics and DNA synthesis innovations. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapid expansion of biotechnology and pharmaceutical industries, increasing government support for life sciences research, and growing investments in synthetic biology and gene therapy. For instance, Evonetix completed a US$24 million financing round in February 2023, bringing its total Series B investment to about US$54 million. Evonetix will be able to continue commercially developing its semiconductor chips thanks to the cash.
This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
Report Scope:
- Base Year: 2024
- Forecast Period: 2025-2035
- Study Coverage
- Market Forecast by Service, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Enzymatic DNA Synthesis Market Report 2024 - 2035
Enzymatic DNA Synthesis Market Analysis & Forecast by Service 2024 - 2035 (Revenue USD Bn)
- Oligonucleotide Synthesis
- Gene Synthesis
Enzymatic DNA Synthesis Market Analysis & Forecast by Application 2024 - 2035 (Revenue USD Bn)
- Synthetic Biology
- Genetic Engineering
- Vaccine Development
- Others
Enzymatic DNA Synthesis Market Analysis & Forecast by End-User 2024 - 2035 (Revenue USD Bn)
- Biopharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations
Enzymatic DNA Synthesis Market Analysis & Forecast by Region 2024 - 2035 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Enzymatic DNA Synthesis Market: Service Estimates & Trend Analysis
8. Enzymatic DNA Synthesis Market: Application Estimates & Trend Analysis
9. Enzymatic DNA Synthesis Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Enzymatic DNA Synthesis Market
12. Europe Global Enzymatic DNA Synthesis Market
13. Asia Pacific Global Enzymatic DNA Synthesis Market
14. Latin America Global Enzymatic DNA Synthesis Market
15. MEA Global Enzymatic DNA Synthesis Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Twist Bioscience
- Codex DNA
- DNA Script
- Ansa Biotechnologies
- GenScript Biotech
- Thermo Fisher Scientific
- Integrated DNA Technologies (IDT)
- Ginkgo Bioworks
- Evonetix
- Synthetic Genomics
- ATUM (formerly DNA2.0)
- OriCiro Genomics
- Nuclera
- SGI-DNA (Synthetic Genomics)
- Telesis Bio
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.3 Billion |
| Forecasted Market Value ( USD | $ 3.9 Billion |
| Compound Annual Growth Rate | 26.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
